Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs
- PMID: 12077046
- PMCID: PMC1123452
- DOI: 10.1136/bmj.324.7352.1519
Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs
Comment in
-
Discontinuation of thioridazine. Risks must be balanced.BMJ. 2002 Oct 26;325(7370):967. doi: 10.1136/bmj.325.7370.967/a. BMJ. 2002. PMID: 12399356 Free PMC article. No abstract available.
-
Discontinuation of thioridazine. What happened to thioridazine?BMJ. 2002 Oct 26;325(7370):967. BMJ. 2002. PMID: 12402926 No abstract available.
References
-
- Breckenridge A. Thioridazine: restricted indications and new warnings on cardiotoxicity. London: Committee on Safety of Medicines; 2000.
-
- Medicines Control Agency/Committee on Safety of Medicines. QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance. 2001;27:4.
-
- Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052. - PubMed
-
- Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 1996;60:543–553. - PubMed
-
- Mehtonen O-P, Aranko K, Mälkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand. 1991;84:58–64. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical